| PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer F Loupakis, L Pollina, I Stasi, A Ruzzo, M Scartozzi, D Santini, G Masi, ... J Clin Oncol 27 (16), 2622-2629, 2009 | 506 | 2009 |
| Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab M Scartozzi, E Galizia, S Chiorrini, R Giampieri, R Berardi, C Pierantoni, ... Annals of oncology 20 (2), 227-230, 2009 | 386 | 2009 |
| Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with … M Scartozzi, I Bearzi, R Berardi, A Mandolesi, G Fabris, S Cascinu Journal of clinical oncology 22 (23), 4772-4778, 2004 | 329 | 2004 |
| Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? D Santini, B Vincenzi, R Addeo, C Garufi, G Masi, M Scartozzi, A Mancuso, ... Annals of Oncology 23 (9), 2313-2318, 2012 | 220 | 2012 |
| Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial S Cascinu, R Berardi, R Labianca, S Siena, A Falcone, E Aitini, S Barni, ... The lancet oncology 9 (1), 39-44, 2008 | 175 | 2008 |
| Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers? G Marisi, A Cucchetti, P Ulivi, M Canale, G Cabibbo, L Solaini, FG Foschi, ... World journal of gastroenterology 24 (36), 4152, 2018 | 166 | 2018 |
| Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy M Scartozzi, I Bearzi, C Pierantoni, A Mandolesi, F Loupakis, A Zaniboni, ... Journal of clinical oncology 25 (25), 3930-3935, 2007 | 155 | 2007 |
| VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE‐1 study M Scartozzi, L Faloppi, G Svegliati Baroni, C Loretelli, F Piscaglia, ... International journal of cancer 135 (5), 1247-1256, 2014 | 144 | 2014 |
| Molecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches M Scartozzi, E Galizia, F Freddari, R Berardi, R Cellerino, S Cascinu Cancer treatment reviews 30 (5), 451-459, 2004 | 122 | 2004 |
| Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy C Madeddu, M Deidda, A Piras, C Cadeddu, L Demurtas, M Puzzoni, ... Journal of cardiovascular medicine 17, e12-e18, 2016 | 121 | 2016 |
| Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients M Scartozzi, R Giampieri, E Maccaroni, M Del Prete, L Faloppi, ... British journal of cancer 106 (5), 799-804, 2012 | 120 | 2012 |
| HER2 loss in HER2‐positive gastric or gastroesophageal cancer after trastuzumab therapy: implication for further clinical research F Pietrantonio, M Caporale, F Morano, M Scartozzi, A Gloghini, F De Vita, ... International journal of cancer 139 (12), 2859-2864, 2016 | 117 | 2016 |
| Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: a meta … C Solinas, M Ceppi, M Lambertini, M Scartozzi, L Buisseret, S Garaud, ... Cancer treatment reviews 57, 8-15, 2017 | 106 | 2017 |
| High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable … S Cascinu, M Scartozzi, R Labianca, V Catalano, RR Silva, S Barni, ... British journal of cancer 90 (8), 1521-1525, 2004 | 106 | 2004 |
| Immunotherapy for colorectal cancer: where are we heading? D Basile, SK Garattini, M Bonotto, E Ongaro, M Casagrande, M Cattaneo, ... Expert opinion on biological therapy 17 (6), 709-721, 2017 | 105 | 2017 |
| Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib AC Gardini, E Scarpi, L Faloppi, M Scartozzi, N Silvestris, D Santini, ... Oncotarget 7 (41), 67142, 2016 | 103 | 2016 |
| The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management L Faloppi, M Scartozzi, M Bianconi, G Svegliati Baroni, P Toniutto, ... BMC cancer 14, 1-8, 2014 | 101 | 2014 |
| Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study S Qin, SL Chan, S Gu, Y Bai, Z Ren, X Lin, Z Chen, W Jia, Y Jin, Y Guo, ... The Lancet 402 (10408), 1133-1146, 2023 | 97 | 2023 |
| VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib M Scartozzi, M Bianconi, L Faloppi, C Loretelli, A Bittoni, M Del Prete, ... British journal of cancer 108 (5), 1126-1132, 2013 | 96 | 2013 |
| Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale AC Gardini, L Faloppi, S De Matteis, FG Foschi, N Silvestris, F Tovoli, ... European Journal of Cancer 86, 106-114, 2017 | 94 | 2017 |
